ATE204754T1 - Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie - Google Patents

Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie

Info

Publication number
ATE204754T1
ATE204754T1 AT99910169T AT99910169T ATE204754T1 AT E204754 T1 ATE204754 T1 AT E204754T1 AT 99910169 T AT99910169 T AT 99910169T AT 99910169 T AT99910169 T AT 99910169T AT E204754 T1 ATE204754 T1 AT E204754T1
Authority
AT
Austria
Prior art keywords
fibrate
metformin
hyperglycemia
treatment
pharmaceutical composition
Prior art date
Application number
AT99910169T
Other languages
English (en)
Inventor
Yves Bonhomme
Philippe Briet
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE204754T1 publication Critical patent/ATE204754T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99910169T 1998-02-12 1999-01-30 Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie ATE204754T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801709A FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
PCT/EP1999/000614 WO1999040904A2 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia

Publications (1)

Publication Number Publication Date
ATE204754T1 true ATE204754T1 (de) 2001-09-15

Family

ID=9522912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99910169T ATE204754T1 (de) 1998-02-12 1999-01-30 Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie

Country Status (27)

Country Link
US (1) US6372790B1 (de)
EP (1) EP1054665B1 (de)
JP (1) JP4767411B2 (de)
KR (1) KR100567608B1 (de)
CN (1) CN1151785C (de)
AR (1) AR018286A1 (de)
AT (1) ATE204754T1 (de)
AU (1) AU746821B2 (de)
BR (1) BRPI9907866B8 (de)
CA (1) CA2320039C (de)
CZ (1) CZ290101B6 (de)
DE (1) DE69900249T2 (de)
DK (1) DK1054665T3 (de)
ES (1) ES2162517T3 (de)
FR (1) FR2774591B1 (de)
HU (1) HU224619B1 (de)
ID (1) ID26254A (de)
MY (1) MY118164A (de)
NO (1) NO328314B1 (de)
PL (1) PL196874B1 (de)
PT (1) PT1054665E (de)
RU (1) RU2207850C2 (de)
SK (1) SK283212B6 (de)
TW (1) TW518222B (de)
UA (1) UA70315C2 (de)
WO (1) WO1999040904A2 (de)
ZA (1) ZA991077B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216335T3 (es) * 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
AU2001236457A1 (en) * 2000-01-13 2001-07-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
JP4829411B2 (ja) * 2001-02-23 2011-12-07 キッセイ薬品工業株式会社 Ｃ型慢性肝炎治療剤
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
EP1424070A1 (de) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Zusammensetzung von einem PPAR-alpha Agonisten und Metformin zur Senkung des Serumtriglyceridspiegels
CN1310648C (zh) 2002-12-13 2007-04-18 佳高泰克有限公司 局部纳米颗粒螺甾内酯制剂
AU2004210268B8 (en) * 2003-02-07 2009-06-04 Ajinomoto Co., Inc. Therapeutic agents for diabetes
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
RU2241449C1 (ru) * 2003-09-25 2004-12-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция для лечения диабета (варианты)
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
AR047779A1 (es) 2003-12-19 2006-02-22 Omega Bio Pharma Ip3 Ltd Composiciones y metodos para tratar diabetes
EP1559419A1 (de) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmazeutische Darreichungsformen enthaltend Metformin und ein Fibrat, sowie deren Herstellungsprozesse
CA2555316A1 (en) * 2004-02-09 2005-08-18 Aska Pharmaceutical Co., Ltd. Combined pharmaceutical composition
EP1591114A1 (de) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Verwendung von Metformin und Orlistat zur Behandlung oder Vorbeugung von Obesität
US20060286182A1 (en) * 2005-06-21 2006-12-21 Abeille Pharmaceuticals, Inc. Synergistic cinnamon combinations and methods for enhancing insulin activity
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
BRPI0621942A2 (pt) 2006-08-04 2011-10-18 Aska Pharm Co Ltd preparação que reduz uma concentração de um ácido graxo livre e/ou fibrinogênio no sangue, agente para redução da quantidade de um ácido graxo livre no sangue, agente para redução da quantidade de fibrinogênio no sangue, método de prevenção ou tratamento de hiper-acidemia de ácido graxo livre, sìndrome metabólica, diabetes tipo ii, complicações causadas por diabetes tipo ii, lipotoxicidade, metabolismo anormal de lipìdeos, intoleráncia à glicose, secreção prejudicada de insulina, gordura hepática, lipoproteinemia de hipo-alta densidade, ou trombose, e uso de uma preparação
CN101342164B (zh) * 2007-08-21 2011-04-20 阜新市仙鹤制药有限责任公司 苯扎贝特控释制剂及其制备方法
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
US8765811B2 (en) * 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
CA2878819A1 (en) * 2012-07-10 2014-01-16 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) * 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
EA201692548A1 (ru) 2014-06-18 2017-10-31 ТЕТИС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Минеральные аминокислотные комплексы активных веществ
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
DK3454907T3 (da) 2016-06-03 2020-10-19 Thetis Pharmaceuticals Llc Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
WO2023119100A1 (en) * 2021-12-22 2023-06-29 Mankind Pharma Ltd. Stable pharmaceutical compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2264525B1 (de) * 1974-03-22 1977-11-04 Expl Marques Brevets Et
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
DE3729209A1 (de) 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
NO302481B1 (no) * 1990-10-16 1998-03-09 Takeda Chemical Industries Ltd Polymer for et preparat med forlenget frigjöring, samt preparat med forlenget frigjöring
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Also Published As

Publication number Publication date
ZA991077B (en) 1999-08-11
BRPI9907866B1 (pt) 2017-08-15
HUP0100801A2 (hu) 2001-08-28
KR100567608B1 (ko) 2006-04-04
SK283212B6 (sk) 2003-03-04
TW518222B (en) 2003-01-21
HU224619B1 (hu) 2005-11-28
DE69900249T2 (de) 2002-06-13
EP1054665B1 (de) 2001-08-29
BR9907866A (pt) 2000-10-31
HUP0100801A3 (en) 2001-12-28
FR2774591B1 (fr) 2000-05-05
BRPI9907866B8 (pt) 2021-05-25
MY118164A (en) 2004-09-30
NO328314B1 (no) 2010-01-25
PL342665A1 (en) 2001-07-02
AU2923399A (en) 1999-08-30
DE69900249D1 (de) 2001-10-04
PT1054665E (pt) 2002-02-28
NO20004056D0 (no) 2000-08-11
CA2320039C (en) 2008-07-22
NO20004056L (no) 2000-08-11
WO1999040904A3 (en) 1999-09-30
FR2774591A1 (fr) 1999-08-13
KR20010040925A (ko) 2001-05-15
JP4767411B2 (ja) 2011-09-07
ES2162517T3 (es) 2001-12-16
DK1054665T3 (da) 2001-12-27
UA70315C2 (en) 2004-10-15
US6372790B1 (en) 2002-04-16
CN1290160A (zh) 2001-04-04
ID26254A (id) 2000-12-07
RU2207850C2 (ru) 2003-07-10
SK11562000A3 (sk) 2000-12-11
AR018286A1 (es) 2001-11-14
AU746821B2 (en) 2002-05-02
CZ20002828A3 (cs) 2000-11-15
PL196874B1 (pl) 2008-02-29
HK1034913A1 (en) 2001-11-09
CN1151785C (zh) 2004-06-02
WO1999040904A2 (en) 1999-08-19
CA2320039A1 (en) 1999-08-19
CZ290101B6 (cs) 2002-05-15
JP2002502869A (ja) 2002-01-29
EP1054665A2 (de) 2000-11-29

Similar Documents

Publication Publication Date Title
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
ATE336235T1 (de) (-)(3-trihalomethylphenoxy) (4-halophenyl) zur behandlung von insulinresistenz und typ ii diabetes
DE69710095D1 (de) Pharmazeutische zubereitung zur behandlung von diabetes
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE309206T1 (de) Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
ATE318138T1 (de) Pharmazeutisches mittel zur behandlung von diabetes
EE200000468A (et) Ühendid, nende kasutamine ja farmatseutiline kompositsioon
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ATE236870T1 (de) Substituierte 2-phenyl-1-(3,4-dihydroxy-5- nitrophenyl)-1-ethanone, deren verwendung zur behandlung von erkrankungen des zentralen und periphären nervensystems und diese enthaltende pharmazeutische zusammensetzungen
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE355840T1 (de) Behandlung der diabetes mit thiazolidindione und metformin
EE9700044A (et) Heteroarüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid.
EP1001782A4 (de) 5,6-HETEROARYL-DIPYRIDO (2-3-b:3',2'-f) AZEPINE UND DEREN VERWENDUNG ZUR PROPHYLAXE UND BEHANDLUNG VON HIV-INFEKTIONEN
DE69804659D1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE59905572D1 (de) Substituierte 4-amino-2-aryl-pyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
DE69829763D1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
EE9900036A (et) Uued ühendid ja kompositsioonid trüptaasi aktiivsusega seotud haiguste raviks
DE60017133D1 (de) Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
FI970095A7 (fi) Uudet kemialliset yhdisteet, niiden valmistus ja niiden käyttö lääkeai neena
DE69912670D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification